Group 1 - A total of 67 stocks experienced block trading on September 15, with a total transaction value of 2.22 billion yuan [1] - The top three stocks by transaction value were Hangzhou Steel (2.5 billion yuan), Guangqi Technology (2.23 billion yuan), and Demingli (2.04 billion yuan) [1] - Among the stocks, 10 were traded at par, 4 at a premium, and 53 at a discount; Zhejiang Meida, SF Holding, and HNA Technology had the highest premium rates of 9.04%, 7.06%, and 1.35% respectively [1] Group 2 - The top stocks by institutional buying were Hangzhou Steel (250 million yuan), Jiangsu Leili (198 million yuan), and Haiguang Information (106 million yuan) [2] - Other notable institutional purchases included Caida Securities (63.6 million yuan), BGI (25 million yuan), and Ningde Times (20.9 million yuan) [2] Group 3 - The top stocks by institutional selling included Xinyi Technology (21 million yuan), Ningde Times (20.9 million yuan), and BYD (20.8 million yuan) [3]

Core Points - The core viewpoint of the article is that BGI Genomics (300676) announced the preliminary transfer price of shares at 44.10 yuan per share based on the inquiry subscription situation on September 15 [1] Group 1 - BGI Genomics is conducting a non-public transfer of shares, which will not be executed through centralized bidding or block trading methods [1] - The shares acquired through the inquiry transfer cannot be transferred by the acquirer within six months after the acquisition [1]

Core Viewpoint - The company BGI Genomics announced a preliminary transfer price of 44.1 yuan per share for its non-public share transfer, which is based on the inquiry subscription situation as of September 15, 2025 [1] Summary by Relevant Categories Share Transfer Details - The share transfer is a non-public transfer and will not be conducted through centralized bidding or block trading methods [1] - The shares acquired through this inquiry transfer cannot be transferred by the acquirer within six months after the acquisition [1] Investor Profile - The acquirer of the shares will be institutional investors who possess the necessary pricing capability and risk tolerance [1]

证券代码：300676 证券简称：华大基因 公告编号：2025-051 深圳华大基因股份有限公司 股东询价转让定价情况提示性公告 股东深圳华大基因科技有限公司保证向深圳华大基因股份有限公司提供的信息内容不存在 任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据2025年9月15日询价申购情况，深圳华大基因股份有限公司（以下简称公司） 股东深圳华大基因科技有限公司询价转让（以下简称本次询价转让）初步确定的转 让价格为44.10元/股； 本次询价转让为非公开转让，不通过集中竞价交易方式或大宗交易方式进行，不属 于通过二级市场减持。受让方通过询价转让受让的股份，在受让后6个月内不得转 让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资者。 深圳华大基因股份有限公司董事会 2025 年 9 月 15 日 （一）本次询价转让尚存在拟转让股份被司法冻结、扣划等风险。询价转让的最终 结果以中国证券登记结算有限责任公司深圳分公司最终办理结果为准。 （二）本次询价转让不会导致公司控制权发 ...

Group 1 - On September 15, BGI Genomics executed a block trade of 522,100 shares, with a transaction value of 25 million yuan, accounting for 2.98% of the total trading volume for that day [1][2] - The transaction price was 47.88 yuan, representing a 10% discount compared to the market closing price of 53.2 yuan [1][2]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司或上市公司）近日收到公司持股5% 以上股东深圳生华投资企业（有限合伙）（以下简称生华投资）的通知，获悉生华 投资将其持有的部分公司股份办理了解除质押及再质押，相应的解除质押及再质押 登记手续已通过中国证券登记结算有限责任公司深圳分公司办理完毕。现将具体内 容公告如下： 一、股东股份解除质押及再质押的基本情况 | 股东名称 | 是否为控股 股东或第一 | 本次解除质 | 占其所持股 | 占公司 | 质押起始 | 质押解除日 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 押股份数量 | | 总股本 | | | 质权人 | | | 大股东及其 | | 份比例 | | 日期 | 期 | | | | 一致行动人 | （股） | | 比例 | | | | | 深圳生华投资 | | | | | | | 中国银行股份 | | 企业（有限合 | 否 | 4,850,000 | 15.23% | 1.16% | 2024/ ...

Group 1 - Baiyang Pharmaceutical plans to strategically invest in Jikun Pharmaceutical by acquiring a 24% stake, securing rights to the innovative drug for pulmonary fibrosis, JK1033, and gaining priority purchase rights for all global compound rights of Jikun Pharmaceutical's products [1] - Qianjin Pharmaceutical received approval from the China Securities Regulatory Commission to issue shares and purchase stakes in Hunan Qianjin Xiangjiang Pharmaceutical (28.92%) and Hunan Qianjin Xieli (68%), enhancing its collaboration in the western medicine sector and supporting its "one main, two auxiliary" strategy [2] - BGI Genomics' major shareholder, Shenzhen BGI Genomics Technology Co., plans to transfer 4% of its shares (16.73 million shares) through a pricing inquiry to meet funding needs for cutting-edge technology incubation in cell and spatiotemporal genomics [3] Group 2 - Suoyuan Biotech's key ENLIGHTEN trial results were published in the prestigious journal JAMA Psychiatry, showing significant efficacy of DB104 (Liafensine) in treatment-resistant depression patients with the ANK3 biomarker, marking a breakthrough in precision medicine for mental health [4] - Betta Pharmaceuticals intends to list on the Hong Kong Stock Exchange, reporting a revenue of 1.731 billion yuan in the first half of 2025, a 15.37% increase, but a net profit decline of 37.53% to 140 million yuan, indicating challenges despite growth in revenue [5]

Group 1 - The core point of the news is that BGI Genomics (华大基因) is undergoing a share transfer plan initiated by its controlling shareholder, BGI Group, to raise funds for cutting-edge technology incubation [1][2] - BGI Group plans to transfer 16.73 million shares, representing 4% of the total share capital, to institutional investors with appropriate pricing and risk-bearing capabilities [1][2] - The funds raised from the share transfer will be prioritized for supporting the incubation of new productivity directions in advanced technology [2] Group 2 - BGI Genomics is positioned as the strongest platform for industrialization and commercialization within BGI Group, focusing on core advantages in reproductive health, cancer prevention, chronic disease management, and infectious disease diagnosis [3] - The company is currently in a critical business transformation period, launching new products aimed at enhancing public health and personalized health management [3] - Future growth drivers for BGI Genomics include increasing health demands due to demographic changes, urgent needs for major disease prevention, and ongoing support from policies and payment systems [3]

Core Viewpoint - The controlling shareholder of BGI Genomics plans to transfer 16.73 million shares, representing 4% of the total share capital, to support cutting-edge technology incubation, indicating a strategic focus on long-term growth and innovation [1][2]. Group 1: Share Transfer Details - The share transfer will be conducted through a non-public inquiry transfer, not affecting the secondary market through traditional reduction methods [1]. - The transferee must be an institutional investor with appropriate pricing capabilities and risk tolerance, and the shares cannot be transferred within six months post-acquisition [1]. Group 2: Strategic Implications - The funds raised from the share transfer will be prioritized for supporting the incubation of new productivity technologies, aligning with BGI's long-term vision [2]. - BGI Genomics aims to leverage its position as a commercialization platform for BGI Group's technological advancements, potentially translating innovations into predictable revenue growth [2]. Group 3: Business Transition and Focus - BGI Genomics is currently undergoing a critical business transition, addressing common industry pain points such as complexity, high costs, and barriers to interpretation and consultation [2]. - The company is increasing its investment in research and development to enhance automation and intelligence capabilities, aiming to expand its business boundaries and improve service value [2].

华大基因（300676）(300676.SZ)发布股东询价转让计划书，本次拟参与询价转让的股东为深圳华大基 因科技有限公司(以下称华大控股或出让方)，出让方拟转让股份总数为1673.27万股，占公司总股本的比 例为4.00%。 ...